Lymphocyte Function and Response to Chemo-immunotherapy in Patients with Metastatic Melanoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 1977 Dec 1

PMID 597473

Citations 8

Authors

N Thatcher

M K Palmer

N Gasiunas

D Crowther

Affiliations

Soon will be listed here.

Abstract

Thirty-eight patients with metastatic melanoma were investigated for lymphocyte function immediately prior to chemo-immunotherapy. The pre-treatment immune tests were compared with normal control values and with response to therapy. The "non-responder" group (but not "responder") had significantly reduced values for lymphocyte, null-cell and E-rosette-cell counts compared with controls. Lymphocytoxicity ( using a Chang target cell) showed the same pattern, with depression of direct and K-cell cytotoxic capacity in non-responders compared with controls. Eight patients were studied sequentially whilst on treatment, and demonstrated considerable change (not statistically significant) in lymphocytotoxicity, an untreated "control" patient showed little variation. "Recall"-antigen skin testing showed no statistically significant difference between the patient groups. The data indicate that "non-T-cell activity" may be associated with response to chemo-immunotherapy.

Citing Articles

Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination.

Heine A, Flores C, Gevensleben H, Diehl L, Heikenwalder M, Ringelhan M Oncoimmunology. 2017; 6(8):e1338995.

PMID: 28920004 PMC: 5593699. DOI: 10.1080/2162402X.2017.1338995.

Natural killer activity in patients with biopsy-proven liver disease.

Serdengecti S, Jones D, Holdstock G, Wright R Clin Exp Immunol. 1981; 45(2):361-4.

PMID: 7318258 PMC: 1537378.

Cell mediated immune response in miniature Sinclair swine bearing cutaneous melanomas.

Jones D, Amoss Jr M Can J Comp Med. 1982; 46(2):209-11.

PMID: 7093814 PMC: 1320283.

Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.

Thatcher N, Swindell R, Crowther D Clin Exp Immunol. 1979; 36(3):456-64.

PMID: 487647 PMC: 1537740.

Lymphocyte response to mitogens in patients with malignant melanoma.

Noack M, BLOEDHORN H, HERRMANN W Arch Dermatol Res. 1979; 264(3):351-5.

PMID: 464653 DOI: 10.1007/BF00412664.

References

Holm G, Perlmann P, Werner B . PHYTOHAEMAGGLUTININ-INDUCED CYTOTOXIC ACTION OF NORMAL LYMPHOID CELLS ON CELLS IN TISSUE CULTURE. Nature. 1964; 203:841-3. DOI: 10.1038/203841a0. View

Morton D, Eilber F, Malmgren R, Wood W . Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970; 68(1):158-63; discussion 163-4. View

Lay W, Mendes N, Bianco C, NUSSENZWEIG V . Binding of sheep red blood cells to a large population of human lymphocytes. Nature. 1971; 230(5295):531-2. DOI: 10.1038/230531a0. View

Harding B, Pudifin D, Gotch F, MacLennan I . Cytotoxic lymphocytes from rats depleted of thymus processed cells. Nat New Biol. 1971; 232(29):80-2. DOI: 10.1038/newbio232080a0. View

Jondal M, Holm G, Wigzell H . Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med. 1972; 136(2):207-15. PMC: 2139198. DOI: 10.1084/jem.136.2.207. View

Bianco C, Patrick R, NUSSENZWEIG V . A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J Exp Med. 1970; 132(4):702-20. PMC: 2138865. DOI: 10.1084/jem.132.4.702. View

Ziegler J, Lewis M, Luyombya J, Kiryabwire J . Immunologic studies in patients with malignant melanoma in Uganda. Br J Cancer. 1969; 23(4):729-34. PMC: 2008492. DOI: 10.1038/bjc.1969.89. View

Perlmann P, Holm G . Cytotoxic effects of lymphoid cells in vitro. Adv Immunol. 1969; 11:117-93. DOI: 10.1016/s0065-2776(08)60479-4. View

Whitehead R, Thatcher J, Teasdale C, Roberts G, Hughes L . T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro. Lancet. 1976; 1(7955):330-3. DOI: 10.1016/s0140-6736(76)90085-4. View

10.

OToole C, Stejskal V, Perlmann P, Karlsson M . Lymphoid cells mediating tumor-specific cytotoxicity to carcinoma of the urinary bladder. Separation of the effector population using a surface marker. J Exp Med. 1974; 139(3):457-66. PMC: 2139543. DOI: 10.1084/jem.139.3.457. View

11.

Berkelhammer J, Mastrangelo M, Laucius J, Bodurtha A, Prehn R . Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors. Int J Cancer. 1975; 16(4):571-8. DOI: 10.1002/ijc.2910160407. View

12.

Hersey P, Edwards A, Edwards J, Adams E, Milton G, Nelson D . Specificity of cell-mediated cytotoxicity against human melanoma lines: evidence for "non-specific" killing by activated T-cells. Int J Cancer. 1975; 16(1):173-83. DOI: 10.1002/ijc.2910160119. View

13.

De Vries J, Cornain S, Rumke P . Cytotoxity of non-T versus T-lymphocytes from melanoma patients and healthy donors on short- and long-term cultured melanoma cells,. Int J Cancer. 1974; 14(4):427-34. DOI: 10.1002/ijc.2910140402. View

14.

MacLennan I . Antibody in the induction and inhibition of lymphocyte cytotoxicity. Transplant Rev. 1972; 13:67-90. DOI: 10.1111/j.1600-065x.1972.tb00060.x. View

15.

Wybran J, Fudenberg H . Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases. J Clin Invest. 1973; 52(5):1026-32. PMC: 302356. DOI: 10.1172/JCI107267. View

16.

Papatestas A, Kark A . Peripheral lymphocyte counts in breast carcinoma. An index of immune competence. Cancer. 1974; 34(6):2014-7. DOI: 10.1002/1097-0142(197412)34:6<2014::aid-cncr2820340620>3.0.co;2-q. View

17.

Heppner G, STOLBACH L, Byrne M, CUMMINGS F, McDonough E, Calabresi P . Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma. Int J Cancer. 1973; 11(2):245-60. DOI: 10.1002/ijc.2910110202. View

18.

Takasugi M, Mickey M, Terasaki P . Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res. 1973; 33(11):2898-902. View

19.

Fossati G, Colnaghi M, Porta G, Cascinelli N, Veronesi U . Cellular and humoral immunity against human malignant melanoma. Int J Cancer. 1971; 8(2):344-50. DOI: 10.1002/ijc.2910080221. View

20.

Jondal M, Pross H . Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations. Int J Cancer. 1975; 15(4):596-605. DOI: 10.1002/ijc.2910150409. View